Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder effects of apathy/anhedonia and fatigue

Journal of Clinical Psychopharmacology

Volumn 34, Issue 6, 2014, Pages 755-759

  Rizvi, Sakina J ^a,b   Geraci, Joseph ^b,c   Ravindran, Arun ^a,d   Kennedy, Sidney H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; CENTRAL STIMULANT AGENT;

ANHEDONIA; APATHY; APATHY EVALUATION SCALE; ASSESSMENT OF HUMANS; COMORBIDITY; CORRELATION ANALYSIS; DEMOGRAPHY; DOPAMINERGIC SYSTEM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FATIGUE; GENERALIZED ANXIETY DISORDER; GENETIC POLYMORPHISM; HUMAN; INTENTION TO TREAT ANALYSIS; LASSITUDE; LETTER; MAJOR DEPRESSION; MENTAL CONCENTRATION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTIVATION; MULTICENTER STUDY (TOPIC); MULTIDIMENSIONAL ASSESSMENT OF FATIGUE; OSMOTIC RELEASE ORAL SYSTEM; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SADNESS; SECONDARY ANALYSIS; SOCIAL PHOBIA; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANHEDONIA; APATHY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER, MAJOR; FATIGUE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925656535     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000211     Document Type: Letter

References (20)

1. Warden D, Rush AJ, Trivedi MH, et al. The STAR∗D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-459.
2. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26-36.
3. Nutt DJ. Relationship of neurotransmitters to the symptoms ofmajor depressive disorder. J Clin Psychiatry. 2008;69(suppl E1):4-7.
4. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;16(2):CD006722.
5. Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101-1107.
6. Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(suppl 1):S29-S37.
7. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-353.
8. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69:87-94.
9. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
10. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26:653-656.
11. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143-162.
12. Bormann J, Shively M, Smith TL, et al. Measurement of fatigue in HIV-positive adults: reliability and validity of the Global Fatigue Index. J Assoc Nurses AIDS Care. 2001;12:75-83.
13. Chou PA. Optimal partitioning for classification and regression trees. IEEE Trans Pattern Anal Mach Intell. 1991;13:340-354.
14. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol. 2006;16:391-402.
15. Meyer JH, McNeely HE, Sagrati S, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006;163:1594-1602.
16. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64:327-337.
17. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43.
18. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008;22:843-848.
19. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25:189-198.
20. Trajkovi G, Starevi V, Latas M, et al. Reliability of the Hamilton Rating Scale for Depression: a meta-analysis over a period of 49 years. Psychiatry Res. 2011;189:1-9.